Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15259128 | 0.92 | EPHX2 (0.43) | SMN1; SMN2HDAC1HDAC3HDAC6HDAC4 | |
| SCHEMBL8592233 | 0.90 | SMN1; SMN2 (0.46) | SMN1; SMN2HDAC1HDAC3HDAC6HDAC4 | |
| SCHEMBL8546299 | 0.89 | SMN1; SMN2 (0.51) | SMN1; SMN2HDAC1HDAC6CA2CA1 | |
| SCHEMBL8611974 | 0.89 | HDAC3 (0.45) | SMN1; SMN2HDAC1HDAC3HDAC6HDAC4 | |
| SCHEMBL8593789 | 0.88 | CA1 (0.47) | HDAC1HDAC3HDAC6HDAC4CA2 | |
| SCHEMBL8591614 | 0.87 | SMN1; SMN2 (0.47) | SMN1; SMN2HDAC1HDAC3HDAC6HDAC4 | |
| SCHEMBL8578411 | 0.85 | HDAC3 (0.47) | SMN1; SMN2HDAC1HDAC3 | |
| SCHEMBL15259127 | 0.83 | EPHX2 (0.57) | SMN1; SMN2HDAC1HDAC6CA2CA1 | |
| SCHEMBL8544019 | 0.82 | SMN1; SMN2 (0.51) | SMN1; SMN2HDAC1HDAC3HDAC6HDAC4 | |
| SCHEMBL8611986 | 0.82 | ALDH1A1 (0.42) | SMN1; SMN2HDAC1HDAC3HDAC6HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328085-B2 | Heterocyclic compounds and expansion agents for hematopoietic stem cells | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-05-03 | — | — | US | disclosed |
| US-20130245255-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20120128640-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245255-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | HCLS1, RUNX1, RCC1 | SMN1; SMN2 555/4885HDAC1 135/4885HDAC3 116/4885 |
| US-20120128640-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | HCLS1, RUNX1, RCC1 | SMN1; SMN2 555/4885HDAC1 135/4885HDAC3 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.